Department of Medicine, Faculty of Medicine, Kuwait University, State of Kuwait, PO BOX: 24923-23110 SAFAT, Jabriya, Kuwait.
Department of Hematology, Kuwait Cancer Center, Shuwaikh, Kuwait.
BMC Cancer. 2024 May 13;24(1):584. doi: 10.1186/s12885-024-12343-1.
In chronic lymphocytic leukaemia (CLL), comorbidities assessed by the CLL comorbidity index (CLL-CI) have been associated with outcomes in Western cohorts. We conducted a retrospective analysis of an unselected Middle Eastern cohort of newly diagnosed CLL patients seen at the Kuwait Cancer Control Center (n = 300). Compared to Western studies, these Middle Eastern patients were diagnosed at a younger age (median of 59) and had a higher comorbidity burden (69% non-low risk CLL-CI). A higher CLL-CI score was independently associated with significantly shorter event-free survival and greater risk of death. Our analysis demonstrates that CLL-CI is a valuable tool for comorbidity assessment and prognostic influence in (relatively young) Middle Eastern CLL patients.
在慢性淋巴细胞白血病（CLL）中，由 CLL 合并症指数（CLL-CI）评估的合并症与西方队列的结局相关。我们对科威特癌症控制中心（n=300）新诊断的 CLL 患者进行了一项回顾性分析，这些患者为未经选择的中东队列。与西方研究相比，这些中东患者的诊断年龄更年轻（中位年龄 59 岁），合并症负担更高（69%非低危 CLL-CI）。较高的 CLL-CI 评分与无事件生存时间明显缩短和死亡风险增加独立相关。我们的分析表明，CLL-CI 是评估（相对年轻的）中东 CLL 患者合并症和预后影响的有用工具。
